Elaprase® (idursulfase)

Elaprase (idursulfase) is covered only for the FDA‑approved indication of mucopolysaccharidosis type II (Hunter syndrome) and is excluded for non‑FDA uses. Approval requires documented deficient iduronate‑2‑sulfatase activity or a pathogenic IDS gene mutation, prescription by or consultation with a geneticist, endocrinologist, metabolic disorder or lysosomal storage disorder specialist, is authorized for 12 months, and the recommended dose is 0.5 mg/kg IV once weekly.

"Elaprase (idursulfase) is indicated for the treatment of individuals with mucopolysaccharidosis type II (MPS II; Hunter syndrome)."

Sign up to see full coverage criteria, indications, and limitations.